First Clinical Study with Novel Serotype E Botulinum Toxin Confirmed Favorable Safety and Differentiated Efficacy Profile
RBV Capital (RBV LP) is a life sciences venture capital fund established in 2014 that invests into innovative biomedical projects
At RBV Capital we build a diversified investment portfolio composed of early to market stage products. Our investment strategy capitalises upon the coming convergence of the biological, chemical, engineering and information technologies. We are interested in biopharmaceuticals, biomedical technology and services, bioinformatics and healthcare IT, medical devices and innovative healthcare providers as well as cross-discipline companies.
Bonti Raises $11.7 million in an Oversubscribed Series B Financing to Advance Development of Lead Product EB-001
NEWPORT BEACH, CA, USA – April 14, 2017 – Bonti, a privately-held, clinical-stage biotechnology company, today announced it successfully secured $11.7 million in a Series B financing. Proceeds from the round will be used to continue developing EB-001, a unique botulinum neurotoxin, for its targeted aesthetic and therapeutic indications with multi-billion dollar addressable market opportunities.